Genetic factors underlying attention and impulsivity: Mouse models of attention-deficit/hyperactivity disorder

Current Opinion in Behavioral Sciences

Volumn 2, Issue , 2015, Pages 46-51

  Itohara, Shigeyoshi ^a   Kobayashi, Yuki ^a   Nakashiba, Toshiaki ^a  

^a RIKEN BRAIN SCIENCE INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ACTIN; ACTIN DEPOLYMERIZING FACTOR; CATECHOL METHYLTRANSFERASE; COFILIN; DAT1 PROTEIN; DOPAMINE 4 RECEPTOR; DOPAMINE TRANSPORTER; DYSBINDIN; FRAGILE X MENTAL RETARDATION PROTEIN; GUANYLATE CYCLASE; GUANYLYL CYCLASE C; NEUROFIBROMIN; NICOTINIC RECEPTOR; RHODOPSIN KINASE; SEROTONIN 2C RECEPTOR; UNCLASSIFIED DRUG;

ATTENTION DEFICIT DISORDER; FRAGILE X SYNDROME; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC MODEL; GENOTYPE ENVIRONMENT INTERACTION; HEREDITY; HUMAN; HUMAN GENETICS; HYPERACTIVITY; IMPULSIVENESS; KNOCKOUT MOUSE; MONOAMINERGIC NERVE; MOUSE; NERVE CELL NETWORK; NERVE CELL PLASTICITY; NEUROFIBROMATOSIS; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPIC VARIATION; POSTSYNAPTIC MEMBRANE; PRESYNAPTIC MEMBRANE; RECOMBINANT INBRED STRAIN; REVIEW; SELECTIVE ATTENTION; SIGNAL TRANSDUCTION; X CHROMOSOME; Y CHROMOSOME;

EID: 84922621294     PISSN: None     EISSN: 23521546     Source Type: Journal    
DOI: 10.1016/j.cobeha.2014.09.002     Document Type: Review

References (70)

1. Association A.P. Diagnostic and statistical manual of mental disorders: DSM-5 2013, American Psychiatric Publishing Inc. 5th ed.
2. Petersen S.E., Posner M.I. The attention system of the human brain: 20 years after. Annu Rev Neurosci 2012, 35:73-89.
3. Fineberg N.A., et al. Probing compulsive and impulsive behaviors, from animal models to endophenotypes: a narrative review. Neuropsychopharmacology 2010, 35:591-604.
4. Whelan R., et al. Adolescent impulsivity phenotypes characterized by distinct brain networks. Nat Neurosci 2012, 15:920-925.
5. Dickstein S.G., et al. The neural correlates of attention deficit hyperactivity disorder: an ALE meta-analysis. J Child Psychol Psychiatry 2006, 47:1051-1062.
6. Valera E.M., et al. Meta-analysis of structural imaging findings in attention-deficit/hyperactivity disorder. Biol Psychiatry 2007, 61:1361-1369.
7. Gomez R., Corr P.J. ADHD and personality: a meta-analytic review. Clin Psychol Rev 2014, 34:376-388.
8. Fan J., et al. Functional deficits of the attentional networks in autism. Brain Behav 2012, 2:647-660.
9. Clark L. Sustained attention deficit in bipolar disorder. Br J Psychiatr 2002, 180:313-319.
10. Crespo-Eguilaz N., Magallon S., Narbona J. Procedural skills and neurobehavioral freedom. Front Hum Neurosci 2014, 8:p449.
11. Faraone S.V., et al. Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatr 2005, 57:1313-1323.
12. Cook E.H., et al. Association of attention-deficit disorder and the dopamine transporter gene. Am J Hum Genet 1995, 56:993-998.
13. Gizer I.R., Ficks C., Waldman I.D. Candidate gene studies of ADHD: a meta-analytic review. Hum Genet 2009, 126:51-90.
14. Wu J., et al. Role of dopamine receptors in ADHD: a systematic meta-analysis. Mol Neurobiol 2012, 45:605-620.
15. Franke B., Neale B.M., Faraone S.V. Genome-wide association studies in ADHD. Hum Genet 2009, 126:13-50.
16. Elia J., et al. Genome-wide copy number variation study associates metabotropic glutamate receptor gene networks with attention deficit hyperactivity disorder. Nat Genet 2012, 44:78-84.
17. Russell V.A. Overview of animal models of attention deficit hyperactivity disorder (ADHD). Curr Protoc Neurosci Chapter 9 2011, Unit9 35.
18. Gainetdinov R.R., et al. Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. Science 1999, 283:397-401.
19. Ralph R.J., et al. Prepulse inhibition deficits and perseverative motor patterns in dopamine transporter knock-out mice: differential effects of D1 and D2 receptor antagonists. J Neurosci 2001, 21:305-313.
20. Yamashita M., et al. Norepinephrine transporter blockade can normalize the prepulse inhibition deficits found in dopamine transporter knockout mice. Neuropsychopharmacology 2006, 31:2132-2139.
21. Yamashita M., et al. Impaired cliff avoidance reaction in dopamine transporter knockout mice. Psychopharmacology (Berl) 2013, 227:741-749.
22. Young J.W., et al. Increased risk-taking behavior in dopamine transporter knockdown mice: further support for a mouse model of mania. J Psychopharmacol 2011, 25:934-943.
23. Chen R., et al. Abolished cocaine reward in mice with a cocaine-insensitive dopamine transporter. Proc Natl Acad Sci USA 2006, 103:9333-9338.
24. O'Neill B., Gu H.H. Amphetamine-induced locomotion in a hyperdopaminergic ADHD mouse model depends on genetic background. Pharmacol Biochem Behav 2013, 103:455-459.
25. Leo D., Gainetdinov R.R. Transgenic mouse models for ADHD. Cell Tissue Res 2013, 354:259-271.
26. Young J.W., et al. The effect of reduced dopamine D4 receptor expression in the 5-choice continuous performance task: Separating response inhibition from premature responding. Behav Brain Res 2011, 222:183-192.
27. Robbins T.W. The 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry. Psychopharmacology (Berl) 2002, 163:362-380.
28. Young J.W., et al. The 5-choice continuous performance test: evidence for a translational test of vigilance for mice. PLoS One 2009, 4:4227.
29. Papaleo F., et al. Effects of sex COMT genotype on environmentally modulated cognitive control in F mice. Proc Natl Acad Sci USA 2012, 109:20160-20165.
30. Papaleo F., et al. Epistatic interaction between COMT and DTNBP1 modulates prefrontal function in mice and in humans. Mol Psychiatry 2014, 19:311-316.
31. Dickman D.K., Davis G.W. The schizophrenia susceptibility gene dysbindin controls synaptic homeostasis. Science 2009, 326:1127-1130.
32. Gong R., et al. Role for the membrane receptor guanylyl cyclase-C in attention deficiency and hyperactive behavior. Science 2011, 333:1642-1646.
33. Li J., et al. Association between polymorphisms in serotonin 2C receptor gene and attention-deficit/hyperactivity disorder in Han Chinese subjects. Neurosci Lett 2006, 407:107-111.
34. Xu X., et al. Investigation of the serotonin 2C receptor gene in attention deficit hyperactivity disorder in UK samples. BMC Res Notes 2009, 2:p71.
35. Pennanen L., et al. Impact of serotonin (5-HT)2C receptors on executive control processes. Neuropsychopharmacology 2013, 38:957-967.
36. Hahn B., Shoaib M., Stolerman I.P. Involvement of the prefrontal cortex but not the dorsal hippocampus in the attention-enhancing effects of nicotine in rats. Psychopharmacology (Berl) 2003, 168:271-279.
37. Rigbi A., et al. Why do young women smoke? V. Role of direct and interactive effects of nicotinic cholinergic receptor gene variation on neurocognitive function. Genes Brain Behav 2008, 7:164-172.
38. Guillem K., et al. Nicotinic acetylcholine receptor beta2 subunits in the medial prefrontal cortex control attention. Science 2011, 333:888-891.
39. Bailey C.D., et al. The nicotinic acetylcholine receptor alpha5 subunit plays a key role in attention circuitry and accuracy. J Neurosci 2010, 30:9241-9252.
40. Tian M.K., et al. Plasticity of prefrontal attention circuitry: upregulated muscarinic excitability in response to decreased nicotinic signaling following deletion of alpha5 or beta2 subunits. J Neurosci 2011, 31:8-63.
41. Hoyle E., et al. Impaired performance of alpha7 nicotinic receptor knockout mice in the five-choice serial reaction time task. Psychopharmacology (Berl) 2006, 189:211-223.
42. Young J.W., et al. Impaired attention is central to the cognitive deficits observed in alpha 7 deficient mice. Eur Neuropsychopharmacol 2007, 17:145-155.
43. Stergiakouli E., et al. Investigating the contribution of common genetic variants to the risk and pathogenesis of ADHD. Am J Psychiatry 2012, 169:186-194.
44. Krueger D.D., Bear M.F. Toward fulfilling the promise of molecular medicine in fragile X syndrome. Annu Rev Med 2011, 62:411-429.
45. Torrioli M., et al. Treatment with valproic acid ameliorates A.D.H.D. symptoms in fragile X. syndrome boys. Am F J. Med Genet A. 2010, 152A:1420-1427.
46. Ronesi J.A., et al. Disrupted Homer scaffolds mediate abnormal mGluR5 function in a mouse model of fragile X syndrome. Nat Neurosci 2012, 15:431-440. S1.
47. Moon J., et al. Attentional dysfunction, impulsivity, and resistance to change in a mouse model of fragile X syndrome. Behav Neurosci, 2006, 120:1367-1379.
48. Kramvis I., et al. Hyperactivity, perseveration and increased responding during attentional rule acquisition in the Fragile X mouse model. Front Behav Neurosci 2013, 7:p172.
49. Casten K.S. A.C. Gray, and R.D. Burwell, Discrimination learning and attentional set formation in a mouse model of Fragile X. Behav Neurosci 2011, 125:473-479.
50. Cingolani L.A., Goda Y. Actin in action: the interplay between the actin cytoskeleton and synaptic efficacy. Nat Rev Neurosci 2008, 9:344-356.
51. Bosch M., Hayashi Y. Structural plasticity of dendritic spines. Curr Opin Neurobiol 2012, 22:383-388.
52. Zimmermann A.M., et al. Attention-Deficit/Hyperactivity Disorder-like Phenotype in a Mouse Model with Impaired Actin Dynamics. Biol Psychiatry 2014.
53. Premont R.T., et al. beta2-Adrenergic receptor regulation by GIT1, a G protein-coupled receptor kinase-associated ADP ribosylation factor GTPase-activating protein. Proc Natl Acad Sci U S A 1998, 95:14082-14087.
54. Hoefen R.J., Berk B.C. The multifunctional GIT family of proteins. J Cell Sci 2006, 119(Pt 8):1469-1475.
55. Won H., et al. GIT1 is associated with ADHD in humans and ADHD-like behaviors in mice. Nat Med 2011, 17:566-572.
56. Salatino-Oliveira A., et al. Association study of GIT1 gene with attention-deficit hyperactivity disorder in Brazilian children and adolescents. Genes Brain Behav 2012, 11:864-868.
57. Lee Y.S., Silva A.J. Modeling hyperactivity: of mice and men. Nat Med 2011, 17:541-542.
58. Koth C.W., Cutting L.E., Denckla M.B. The association of neurofibromatosis type 1 and attention deficit hyperactivity disorder. Child Neuropsychol 2000, 6:185-194.
59. Li W., et al. The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1. Curr Biol, 2005, 15:1961-1967.
60. Cui Y., et al. Neurofibromin regulation of ERK signaling modulates GABA release and learning. Cell 2008, 135:549-560.
61. Jensen K., et al. GABA transporter-1 (GAT1)-deficient mice: differential tonic activation of GABAA versus GABAB receptors in the hippocampus. J Neurophysiol 2003, 90:2690-2701.
62. Yang P., et al. Gamma aminobutyric acid transporter subtype 1 gene knockout mice: a new model for attention deficit/hyperactivity disorder. Acta Biochim Biophys Sin (Shanghai) 2013, 45:578-585.
63. Trent S., et al. Biological mechanisms associated with increased perseveration and hyperactivity in a genetic mouse model of neurodevelopmental disorder. Psychoneuroendocrinology 2013, 38:1370-1380.
64. Davies W., et al. Converging pharmacological and genetic evidence indicates a role for steroid sulfatase in attention. Biol Psychiatry 2009, 66:360-367.
65. Humby T., et al. A novel translational assay of response inhibition and impulsivity: effects of prefrontal cortex lesions, drugs used in ADHD, and serotonin 2C receptor antagonism. Neuropsychopharmacology 2013, 38:2150.
66. Davies W., et al. Genetic and pharmacological modulation of the steroid sulfatase axis improves response control; comparison with drugs used in ADHD. Neuropsychopharmacology 2014.
67. Loos M., et al. Independent genetic loci for sensorimotor gating and attentional performance in BXD recombinant inbred strains. Genes Brain Behav 2012, 11:147-156.
68. Loos M., et al. Neuregulin-3 in the mouse medial prefrontal cortex regulates impulsive action. Biol Psychiatry 2014.
69. Zhang D., et al. Neuregulin-3 (NRG3): a novel neural tissue-enriched protein that binds activates ErbB4. Proc Natl Acad Sci U S A 1997, 94:9562-9567.
70. Meier S., et al. Neuregulin 3 is associated with attention deficits in schizophrenia and bipolar disorder. Int J Neuropsychopharmacol 2013, 16:549-556.